VJOncology is committed to improving our service to you

ESMO 2020 | NeoTRIPaPDL1: dynamics of TILs & PD-L1 expression in breast cancer

VJOncology is committed to improving our service to you

Giampaolo Bianchini

Giampaolo Bianchini, MD, of IRCCS San Raffaele Hospital, Milan, Italy, discusses data coming from the NeoTRIPaPDL1 trial (NCT02620280) – a randomized Phase III study evaluating neoadjuvant atezolizumab with carboplatin and nab-paclitaxel in patients with early high-risk and locally advanced triple negative breast cancer. The data presented at ESMO 2020 looked at the role of tumour infiltrating lymphocytes (TILs) and PD-L1 expression in samples collected at baseline, Day 1 of cycle 2 or at surgery. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter